View in EDS HTML Full Text PDF Full Text

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.

Saved in:
Bibliographic Details
Title: Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Authors: Sharmin, Sifat (AUTHOR), Lefort, Mathilde (AUTHOR), Andersen, Johanna Balslev (AUTHOR), Leray, Emmanuelle (AUTHOR), Horakova, Dana (AUTHOR), Havrdova, Eva Kubala (AUTHOR), Alroughani, Raed (AUTHOR), Izquierdo, Guillermo (AUTHOR), Ozakbas, Serkan (AUTHOR), Patti, Francesco (AUTHOR), Onofrj, Marco (AUTHOR), Lugaresi, Alessandra (AUTHOR), Terzi, Murat (AUTHOR), Grammond, Pierre (AUTHOR), Grand'Maison, Francois (AUTHOR), Yamout, Bassem (AUTHOR), Prat, Alexandre (AUTHOR), Girard, Marc (AUTHOR), Duquette, Pierre (AUTHOR), Boz, Cavit (AUTHOR)
Source: CNS Drugs. Nov2021, Vol. 35 Issue 11, p1217-1232. 16p.
Subjects: Natalizumab, Proportional hazards models, Magnetic resonance imaging, Disease relapse, Multiple sclerosis, Fingolimod, Subgroup analysis (Experimental design)
Abstract: Introduction: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. Objective: The aim of this study was to compare the relative effectiveness of natalizumab and fingolimod in RRMS subgroups defined by the baseline demographic and clinical characteristics of interest. Methods: Patients with RRMS who were given natalizumab or fingolimod were identified in a merged cohort from three international registries. Efficacy outcomes were compared across subgroups based on patients' sex, age, disease duration, Expanded Disability Status Scale (EDSS) score, and disease and magnetic resonance imaging (MRI) activity 12 months prior to treatment initiation. Study endpoints were number of relapses (analyzed with weighted negative binomial generalized linear model) and 6-month confirmed disability worsening and improvement events (weighted Cox proportional hazards model), recorded during study therapy. Each patient was weighted using inverse probability of treatment weighting based on propensity score. Results: A total of 5148 patients (natalizumab 1989; fingolimod 3159) were included, with a mean ± standard deviation age at baseline of 38 ± 10 years, and the majority (72%) were women. The median on-treatment follow-up was 25 (quartiles 15–41) months. Natalizumab was associated with fewer relapses than fingolimod (incidence rate ratio [IRR]; 95% confidence interval [CI]) in women (0.76; 0.65–0.88); in those aged ≤ 38 years (0.64; 0.54–0.76); in those with disease duration ≤ 7 years (0.63; 0.53–0.76); in those with EDSS score < 4 (0.75; 0.64–0.88), < 6 (0.80; 0.70–0.91), and ≥ 6 (0.52; 0.31–0.86); and in patients with pre-baseline relapses (0.74; 0.64–0.86). A higher probability of confirmed disability improvement on natalizumab versus fingolimod (hazard ratio [HR]; 95% CI) was observed among women (1.36; 1.10–1.66); those aged > 38 years (1.34; 1.04–1.73); those with disease duration > 7 years (1.33; 1.01–1.74); those with EDSS score < 6 (1.21; 1.01–1.46) and ≥ 6 (1.93; 1.11–3.34); and patients with no new MRI lesion (1.73; 1.19–2.51). Conclusions: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity. [ABSTRACT FROM AUTHOR]
Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 153241256
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sharmin%2C+Sifat%22&quot;&gt;Sharmin, Sifat&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lefort%2C+Mathilde%22&quot;&gt;Lefort, Mathilde&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Andersen%2C+Johanna+Balslev%22&quot;&gt;Andersen, Johanna Balslev&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Leray%2C+Emmanuelle%22&quot;&gt;Leray, Emmanuelle&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Horakova%2C+Dana%22&quot;&gt;Horakova, Dana&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Havrdova%2C+Eva+Kubala%22&quot;&gt;Havrdova, Eva Kubala&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Alroughani%2C+Raed%22&quot;&gt;Alroughani, Raed&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Izquierdo%2C+Guillermo%22&quot;&gt;Izquierdo, Guillermo&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ozakbas%2C+Serkan%22&quot;&gt;Ozakbas, Serkan&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Patti%2C+Francesco%22&quot;&gt;Patti, Francesco&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Onofrj%2C+Marco%22&quot;&gt;Onofrj, Marco&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lugaresi%2C+Alessandra%22&quot;&gt;Lugaresi, Alessandra&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Terzi%2C+Murat%22&quot;&gt;Terzi, Murat&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Grammond%2C+Pierre%22&quot;&gt;Grammond, Pierre&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Grand&#39;Maison%2C+Francois%22&quot;&gt;Grand&#39;Maison, Francois&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Yamout%2C+Bassem%22&quot;&gt;Yamout, Bassem&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Prat%2C+Alexandre%22&quot;&gt;Prat, Alexandre&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Girard%2C+Marc%22&quot;&gt;Girard, Marc&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Duquette%2C+Pierre%22&quot;&gt;Duquette, Pierre&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Boz%2C+Cavit%22&quot;&gt;Boz, Cavit&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22CNS+Drugs%22&quot;&gt;CNS Drugs&lt;/searchLink&gt;. Nov2021, Vol. 35 Issue 11, p1217-1232. 16p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Natalizumab%22&quot;&gt;Natalizumab&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Proportional+hazards+models%22&quot;&gt;Proportional hazards models&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Magnetic+resonance+imaging%22&quot;&gt;Magnetic resonance imaging&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Disease+relapse%22&quot;&gt;Disease relapse&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Multiple+sclerosis%22&quot;&gt;Multiple sclerosis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Fingolimod%22&quot;&gt;Fingolimod&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Subgroup+analysis+%28Experimental+design%29%22&quot;&gt;Subgroup analysis (Experimental design)&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Introduction: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. Objective: The aim of this study was to compare the relative effectiveness of natalizumab and fingolimod in RRMS subgroups defined by the baseline demographic and clinical characteristics of interest. Methods: Patients with RRMS who were given natalizumab or fingolimod were identified in a merged cohort from three international registries. Efficacy outcomes were compared across subgroups based on patients&#39; sex, age, disease duration, Expanded Disability Status Scale (EDSS) score, and disease and magnetic resonance imaging (MRI) activity 12 months prior to treatment initiation. Study endpoints were number of relapses (analyzed with weighted negative binomial generalized linear model) and 6-month confirmed disability worsening and improvement events (weighted Cox proportional hazards model), recorded during study therapy. Each patient was weighted using inverse probability of treatment weighting based on propensity score. Results: A total of 5148 patients (natalizumab 1989; fingolimod 3159) were included, with a mean &#177; standard deviation age at baseline of 38 &#177; 10 years, and the majority (72%) were women. The median on-treatment follow-up was 25 (quartiles 15–41) months. Natalizumab was associated with fewer relapses than fingolimod (incidence rate ratio [IRR]; 95% confidence interval [CI]) in women (0.76; 0.65–0.88); in those aged ≤ 38 years (0.64; 0.54–0.76); in those with disease duration ≤ 7 years (0.63; 0.53–0.76); in those with EDSS score &lt; 4 (0.75; 0.64–0.88), &lt; 6 (0.80; 0.70–0.91), and ≥ 6 (0.52; 0.31–0.86); and in patients with pre-baseline relapses (0.74; 0.64–0.86). A higher probability of confirmed disability improvement on natalizumab versus fingolimod (hazard ratio [HR]; 95% CI) was observed among women (1.36; 1.10–1.66); those aged &gt; 38 years (1.34; 1.04–1.73); those with disease duration &gt; 7 years (1.33; 1.01–1.74); those with EDSS score &lt; 6 (1.21; 1.01–1.46) and ≥ 6 (1.93; 1.11–3.34); and patients with no new MRI lesion (1.73; 1.19–2.51). Conclusions: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=153241256
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40263-021-00860-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 16
        StartPage: 1217
    Subjects:
      – SubjectFull: Natalizumab
        Type: general
      – SubjectFull: Proportional hazards models
        Type: general
      – SubjectFull: Magnetic resonance imaging
        Type: general
      – SubjectFull: Disease relapse
        Type: general
      – SubjectFull: Multiple sclerosis
        Type: general
      – SubjectFull: Fingolimod
        Type: general
      – SubjectFull: Subgroup analysis (Experimental design)
        Type: general
    Titles:
      – TitleFull: Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sharmin, Sifat
      – PersonEntity:
          Name:
            NameFull: Lefort, Mathilde
      – PersonEntity:
          Name:
            NameFull: Andersen, Johanna Balslev
      – PersonEntity:
          Name:
            NameFull: Leray, Emmanuelle
      – PersonEntity:
          Name:
            NameFull: Horakova, Dana
      – PersonEntity:
          Name:
            NameFull: Havrdova, Eva Kubala
      – PersonEntity:
          Name:
            NameFull: Alroughani, Raed
      – PersonEntity:
          Name:
            NameFull: Izquierdo, Guillermo
      – PersonEntity:
          Name:
            NameFull: Ozakbas, Serkan
      – PersonEntity:
          Name:
            NameFull: Patti, Francesco
      – PersonEntity:
          Name:
            NameFull: Onofrj, Marco
      – PersonEntity:
          Name:
            NameFull: Lugaresi, Alessandra
      – PersonEntity:
          Name:
            NameFull: Terzi, Murat
      – PersonEntity:
          Name:
            NameFull: Grammond, Pierre
      – PersonEntity:
          Name:
            NameFull: Grand'Maison, Francois
      – PersonEntity:
          Name:
            NameFull: Yamout, Bassem
      – PersonEntity:
          Name:
            NameFull: Prat, Alexandre
      – PersonEntity:
          Name:
            NameFull: Girard, Marc
      – PersonEntity:
          Name:
            NameFull: Duquette, Pierre
      – PersonEntity:
          Name:
            NameFull: Boz, Cavit
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2021
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 11727047
          Numbering:
            – Type: volume
              Value: 35
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: CNS Drugs
              Type: main
ResultId 1